Erasmus Medical Center
New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues
By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.
GeneCentric, Erasmus University to Research RNA Biomarkers, Therapies for Bladder Cancer
GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.